These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 30772438)

  • 1. Effects of sodium nitroprusside in the acute dizocilpine (MK-801) animal model of schizophrenia.
    Wang X; Ding S; Lu Y; Jiao Z; Zhang L; Zhang Y; Yang Y; Zhang Y; Li W; Lv L
    Brain Res Bull; 2019 Apr; 147():140-147. PubMed ID: 30772438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metformin reverses the schizophrenia-like behaviors induced by MK-801 in rats.
    Wang X; Luo C; Mao XY; Li X; Yin JY; Zhang W; Zhou HH; Liu ZQ
    Brain Res; 2019 Sep; 1719():30-39. PubMed ID: 31121159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MK-801-induced impairments on the trial-unique, delayed nonmatching-to-location task in rats: effects of acute sodium nitroprusside.
    Hurtubise JL; Marks WN; Davies DA; Catton JK; Baker GB; Howland JG
    Psychopharmacology (Berl); 2017 Jan; 234(2):211-222. PubMed ID: 27725997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of striatum and prefrontal cortex in the prevention of amphetamine-induced schizophrenia-like effects mediated by nitric oxide compounds.
    Issy AC; Dos-Santos-Pereira M; Pedrazzi JFC; Kubrusly RCC; Del-Bel E
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Aug; 86():353-362. PubMed ID: 29555252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glutamate receptor 1 phosphorylation at serine 845 contributes to the therapeutic effect of olanzapine on schizophrenia-like cognitive impairments.
    Zhang C; Fang Y; Xu L
    Schizophr Res; 2014 Nov; 159(2-3):376-84. PubMed ID: 25219486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GluN2C/GluN2D subunit-selective NMDA receptor potentiator CIQ reverses MK-801-induced impairment in prepulse inhibition and working memory in Y-maze test in mice.
    Suryavanshi PS; Ugale RR; Yilmazer-Hanke D; Stairs DJ; Dravid SM
    Br J Pharmacol; 2014 Feb; 171(3):799-809. PubMed ID: 24236947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment of a schizophrenic animal model through chronic administration of MK-801 in infancy and social isolation in childhood.
    Liu W; Wang X; Hong W; Wang D; Chen X
    Infant Behav Dev; 2017 Feb; 46():135-143. PubMed ID: 28142061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of nitric oxide-related compounds in the acute ketamine animal model of schizophrenia.
    Kandratavicius L; Balista PA; Wolf DC; Abrao J; Evora PR; Rodrigues AJ; Chaves C; Maia-de-Oliveira JP; Leite JP; Dursun SM; Baker GB; Guimaraes FS; Hallak JE
    BMC Neurosci; 2015 Mar; 16():9. PubMed ID: 25887360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ameliorating effects of berberine on MK-801-induced cognitive and motor impairments in a neonatal rat model of schizophrenia.
    Ghotbi Ravandi S; Shabani M; Bashiri H; Saeedi Goraghani M; Khodamoradi M; Nozari M
    Neurosci Lett; 2019 Jul; 706():151-157. PubMed ID: 31103726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The nitric oxide donor sodium nitroprusside attenuates recognition memory deficits and social withdrawal produced by the NMDA receptor antagonist ketamine and induces anxiolytic-like behaviour in rats.
    Trevlopoulou A; Touzlatzi N; Pitsikas N
    Psychopharmacology (Berl); 2016 Mar; 233(6):1045-54. PubMed ID: 26685991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Nitric Oxide (NO) Donor Sodium Nitroprusside (SNP) and Its Potential for the Schizophrenia Therapy: Lights and Shadows.
    Zoupa E; Pitsikas N
    Molecules; 2021 May; 26(11):. PubMed ID: 34073534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enriched environment prevents cognitive and motor deficits associated with postnatal MK-801 treatment.
    Nozari M; Shabani M; Hadadi M; Atapour N
    Psychopharmacology (Berl); 2014 Nov; 231(22):4361-70. PubMed ID: 24770628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positive Allosteric Modulation of the Muscarinic M1 Receptor Improves Efficacy of Antipsychotics in Mouse Glutamatergic Deficit Models of Behavior.
    Choy KH; Shackleford DM; Malone DT; Mistry SN; Patil RT; Scammells PJ; Langmead CJ; Pantelis C; Sexton PM; Lane JR; Christopoulos A
    J Pharmacol Exp Ther; 2016 Nov; 359(2):354-365. PubMed ID: 27630144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive validity of a MK-801-induced cognitive impairment model in mice: implications on the potential limitations and challenges of modeling cognitive impairment associated with schizophrenia preclinically.
    Brown JW; Rueter LE; Zhang M
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Mar; 49():53-62. PubMed ID: 24269664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repeated but not acute exposure with a low dose range of the nitric oxide (NO) donor sodium nitroprusside (SNP) induces anxiolytic-like behaviour in a dose-independent manner in two different rat models of anxiety.
    Papageorgoulis A; Fallon P; Mpalantes N; Papageorgouli D; Pitsikas N
    Nitric Oxide; 2020 Jun; 99():1-6. PubMed ID: 32194244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of cannabidiol in a MK-801-rodent model of aspects of schizophrenia.
    Gururajan A; Taylor DA; Malone DT
    Behav Brain Res; 2011 Sep; 222(2):299-308. PubMed ID: 21458498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oleanolic acid attenuates MK-801-induced schizophrenia-like behaviors in mice.
    Park SJ; Lee Y; Oh HK; Lee HE; Lee Y; Ko SY; Kim B; Cheong JH; Shin CY; Ryu JH
    Neuropharmacology; 2014 Nov; 86():49-56. PubMed ID: 24997455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persisting cognitive deficits induced by low-dose, subchronic treatment with MK-801 in adolescent rats.
    Li JT; Su YA; Guo CM; Feng Y; Yang Y; Huang RH; Si TM
    Eur J Pharmacol; 2011 Feb; 652(1-3):65-72. PubMed ID: 21114996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of MK-801 treatment across several pre-clinical analyses including a novel assessment of brain metabolic function utilizing PET and CT fused imaging in live rats.
    Daya RP; Bhandari JK; Hui PA; Tian Y; Farncombe T; Mishra RK
    Neuropharmacology; 2014 Feb; 77():325-33. PubMed ID: 24140927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developmental vitamin D deficiency alters MK 801-induced hyperlocomotion in the adult rat: An animal model of schizophrenia.
    Kesby JP; Burne TH; McGrath JJ; Eyles DW
    Biol Psychiatry; 2006 Sep; 60(6):591-6. PubMed ID: 16697353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.